{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"030-605-656-832-783","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"030-605-656-832-783","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8761,"type":"PATENT","title":"University of Chicago","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5987,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8204,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Searched applicants and Owners= \"Chicago Univ \", \"Univ Chicago\", \"\"Chicago University \" NOT \"loyola\"\", \" \"Univ Chic* NOT \"Loyola\" \".
Select more for logical variants
Add to collection
Select the result in the collection and expand by simple families
Add to collection
Total patents: 4656
Searched applicants and Owners= \"Chicago Univ \", \"Univ Chicago\", \"\"Chicago University \" NOT \"loyola\"\", \" \"Univ Chic* NOT \"Loyola\" \".
Select more for logical variants
Add to collection
Select the result in the collection and expand by simple families
Add to collection
Total patents: 4656
(a) an EsxA and/or an EsxB protein and a sortase substrate selected from SdrD, SdrE, IsdA, or IsdB; or
(b) a nucleic acid encoding an EsxA and/or EsxB protein and a sortase substrate selected from SdrD, SdrE, IsdA, or IsdB,for use in a method of eliciting an immune response against a staphylococcus bacterium in a subject."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 1, comprising a combination of Staphylococcus virulence factors, wherein the combination includes more than one of the following Staphylococcus cell surface proteins: SdrD, SdrE, IsdA, or IsdB."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 2, wherein the combination further includes SdrC, Spa, IsdC, ClfA, ClfB, SasF, or combinations thereof."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 3, comprising
(a) two or more of SdrD, SdrE, IsdA, or IsdB proteins, preferably comprising SdrD, SdrE, IsdA, and IsdB proteins; or
(b) one or more nucleic acid molecules encoding two or more SdrD, SdrE, IsdA, or IsdB proteins."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 1 wherein:
(a) the subject is a human;
(b) the composition is formulated in a pharmaceutically acceptable formulation;
(c) the Staphylococcus bacteria is Staphylococcus aureus;
(d) the patient is not provided a Staphylococcus bacterium containing the combination of virulence factors;
(e) the composition is administered more than one time to the subject;
(f) the composition is administered orally;
(g) the composition is administered parenterally, preferably wherein the composition is administered subcutaneously, intramuscularly, or intravenously;
(h) the composition includes a recombinant, non-staphylococcus bacterium containing the SdrD, SdrE, IsdA or IsdB protein, preferably wherein the recombinant non-staphylococcus bacterium is Salmonella; or
(i) the immune response is a protective immune response."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The composition of any of the preceding claims, an adjuvant or further comprising an adjuvant linked to the protein, more preferably wherein the adjuvant is chemically conjugated to the protein."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 1, wherein the EsxA protein is at least 70, 80, or 90% identical to SEQ ID NO:2; or the EsxB protein is at least 70, 80, or 90% identical to SEQ ID NO:4."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The composition of claim 1, wherein:
(a) the SdrD protein is at least 70% identical to SEQ ID NO:6;
(b) the SdrD protein is at least 80% identical to SEQ ID NO:6;
(c) the SdrD protein is at least 90% identical to SEQ ID NO:6;
(d) the SdrE protein is at least 70% identical to SEQ ID NO:8;
(e) the SdrE protein is at least 80% identical to SEQ ID NO:8;
(f) the SdrE protein is at least 90% identical to SEQ ID NO:8;
(g) the IsdA protein is at least 70% identical to SEQ ID NO:10;
(h) the IsdA protein is at least 80% identical to SEQ ID NO:10;
(i) the IsdA protein is at least 90% identical to SEQ ID NO:10;
(j) the IsdB protein is at least 70% identical to SEQ ID NO:12;
(k) the IsdB protein is at least 80% identical to SEQ ID NO:12; or
(l) the IsdB protein is at least 90% identical to SEQ ID NO:12."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A vaccine comprising a pharmaceutically acceptable composition having
(a) an EsxA and/or an EsxB protein and one or more isolated SdrD, SdrE, IsdA, or IsdB proteins, or
(b) a recombinant nucleic acid encoding an EsxA and/or an EsxB protein and one or more of SdrD, SdrE, IsdA, or IsdB proteins,wherein the composition is capable of stimulating an immune response against a Staphylococcus bacteria."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine of claim 9(a):
(i) further comprising an isolated SdrC, Spa, IsdC, ClfA, ClfB or SasF protein;
(ii) comprising an isolated SdrD, an isolated SdrE protein, an isolated IsdA, and an isolated IsdB protein, preferably wherein the composition is contaminated by less than 1% with other Staphylococcus bacterial proteins;
(iii) further comprising an adjuvant, preferably wherein the protein is linked to the adjuvant, more preferably wherein the adjuvant is chemically conjugated to the protein."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine of claim 9(b), further comprising
(i) a recombinant nucleic acid encoding an SdrC, Spa, IsdC, ClfA, ClfB or SasF protein;
(ii) wherein the recombinant nucleic acid contains a heterologous promoter;
(iii) wherein the recombinant nucleic acid is a vector, preferably a plasmid or a viral vector;
(iv) wherein the composition includes a recombinant, non-Staphylococcus bacteria containing the nucleic acid, preferably wherein the recombinant non-Staphylococcus bacteria is Salmonella; or
(v) wherein the composition further comprises an adjuvant."],"number":11,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}